Bortezomib for refractory autoimmunity in pediatrics.
暂无分享,去创建一个
S. Davies | S. Jodele | A. Filipovich | M. Jordan | B. Curtis | P. Khandelwal | R. Marsh | M. Grimley
[1] Y. Qazi,et al. Bortezomib in kidney transplantation , 2015, Current opinion in organ transplantation.
[2] D. Roelen,et al. Proteasome Inhibition Profoundly Affects Activated Human B Cells , 2013, Transplantation.
[3] E. Woodle,et al. Rapid Reduction in Donor-Specific Anti-Human Leukocyte Antigen Antibodies and Reversal of Antibody-Mediated Rejection With Bortezomib in Pediatric Heart Transplant Patients , 2012, Transplantation.
[4] R. Alloway,et al. Clinical and investigational use of proteasome inhibitors for transplant rejection , 2011, Expert opinion on investigational drugs.
[5] R. Alloway,et al. Proteasome inhibitor therapy for antibody‐mediated rejection , 2011, Pediatric transplantation.
[6] E. Woodle,et al. Proteasome inhibitor treatment of antibody-mediated allograft rejection , 2011, Current opinion in organ transplantation.
[7] D. Esseltine,et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. , 2011, The Lancet. Oncology.
[8] Andreas Radbruch,et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation , 2011, Nature Reviews Rheumatology.
[9] P. Terasaki,et al. Protective Immunity Remains Intact After Antibody Removal by Means of Proteasome Inhibition , 2010, Transplantation.
[10] F. Moosig,et al. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma , 2010, Annals of the rheumatic diseases.
[11] R. Alloway,et al. Proteasome Inhibitor-Based Primary Therapy for Antibody-Mediated Renal Allograft Rejection , 2010, Transplantation.
[12] R. Alloway,et al. Proteasome inhibition for antibody-mediated rejection , 2009, Current opinion in organ transplantation.
[13] P. Terasaki,et al. Abrogation of Anti-HLA Antibodies via Proteasome Inhibition , 2009, Transplantation.
[14] R. Alloway,et al. Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection , 2008, Transplantation.
[15] J. Kurtzberg,et al. Posttransplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unrelated donor umbilical cord blood transplantation. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[16] K. Fairfax,et al. Plasma cell development: from B-cell subsets to long-term survival niches. , 2008, Seminars in immunology.
[17] N. Puig,et al. Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients , 2007, Bone Marrow Transplantation.
[18] M. Marques,et al. Laboratory evaluation and transfusion support of patients with autoimmune hemolytic anemia. , 2006, American journal of clinical pathology.
[19] G. Giaccone,et al. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies , 2005, Cancer.
[20] J. Neglia,et al. Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non‐malignant diseases , 2004, British journal of haematology.
[21] Andreas Radbruch,et al. Short-lived Plasmablasts and Long-lived Plasma Cells Contribute to Chronic Humoral Autoimmunity in NZB/W Mice , 2004, The Journal of Experimental Medicine.
[22] M. Viele,et al. Autoimmune hemolytic anemia in patients with SCID after T cell-depleted BM and PBSC transplantation , 1999, Bone Marrow Transplantation.
[23] C. Bollard,et al. Complications of transplant for nonmalignant disorders: autoimmune cytopenias, opportunistic infections, and PTLD. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[24] P. Eckman,et al. Bortezomib for refractory antibody-mediated cardiac allograft rejection. , 2009, Clinical transplants.